copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
KRAS-ERK signaling drives metastasis in colorectal cancer via . . . Background Metastatic colorectal cancer (CRC) harboring KRAS mutations presents a major therapeutic challenge due to its aggressive nature, poor prognosis, and resistance to EGFR-targeted therapies This study aimed to identify novel drivers of metastasis specifically in KRAS-mutant CRC and to elucidate the underlying molecular mechanisms to undercover new therapeutic vulnerabilities Methods
BRAF and KRAS mutations in metastatic colorectal cancer: future . . . In this review, we focus on BRAF and KRAS mutations to understand the mechanisms underlying resistance and improving the response rate, outcomes, and prognosis of patients with mCRC bearing these mutations and to discuss prospective personalized therapies for BRAF - and KRAS -mutant mCRC
Survival impact of NeoRAS wild-type metastatic colorectal cancer: A . . . Background: The “Neo RAS ’’ phenomenon refers to KRAS or NRAS mutant (MT) metastatic colorectal cancer (mCRC) that becomes RAS wild-type (WT) following treatment and may represent a novel indication for anti-epidermal growth factor receptor monoclonal antibodies
KRAS wild-type state predicts survival and is associated to early . . . KRAS mutation status is a candidate marker for predicting survival in patients with metastatic colorectal cancer (mCRC) treated with cetuximab (CTX) We studied the KRAS mutation status of 113 patients with irinotecan refractory mCRC treated with CTX in clinical trials
Treatment of extended RAS BRAF wild-type metastatic colorectal cancer . . . Two drugs of this class, cetuximab and panitumumab, have been used in patients with metastatic colorectal cancer initially without any biomarker requirement Soon, it became clear that responses were mostly observed in patients without mutations in KRAS oncogene
Colorectal Cancer and KRAS BRAF - Medscape With the availability of laboratory tests to identify KRAS and BRAF mutations, of monoclonal antibodies that are effective only in CRC with wild-type KRAS, and of agents for CRC with